Abstract:Background Direct targeting of KRAS is challenging and represents an unmet need. We identified SLC25A22, a mitochondrial glutamate transporter, as a potential therapeutic target in KRAS mutant colorectal cancer (CRC). In this study, we reveal that SLC25A22 underlies mutant KRAS-induced immune suppression in CRC. Methods Immune cell infiltration was determined by flow cytometry. The immunosuppressive effect and migration of MDSC were estimated by T cell suppression assay and transwell assay, respectively. Results Tumors from ApcMin/+KrasG12DVillin-Cre mice demonstrated marked infiltration in immunosuppressive myeloid-derived suppressor cells (MDSC) (P<0.001), but reduced T-cells (CD4+/CD8+) (P<0.05) (IDDF2021-ABS-0183 Figure 1. Kras-mutated tumors exhibit an immune-suppressive microenvironment). Tumor organoids derived from ApcMin/+KrasG12D Villin-Cre with or without SLC25A22 were injected into C57 mice. SLC25A22 knockout severely impaired tumor growth, with reduced MDSC (P<0.05) but increased CD4+/CD8+ T-cells (P<0.05, P<0.01). Consistent data were obtained from the syngeneic mouse models of murine CRC cell lines with Slc25a22 knockout. And there was a negative correlation between the percentage of MDSC and that of CD8+ T-cells in the xenograft tumour tissues (R2=0.592, P<0.001). Indeed, T cell proliferation was impaired after being co-cultured with MDSC in Vitro. These results suggested that knockout of Slc25a22 reversed mutant KRAS-driven immune suppression, especially reduced the immunosuppressive MDSC infiltration (IDDF2021-ABS-0183 Figure 2. SLC25A22 knockout impaired tumor growth and reversed mutant KRAS-driven immune suppression in syngeneic mice, IDDF2021-ABS-0183 Figure 3. SLC25A22 knockout impaired tumor growth and reversed mutant KRAS-driven immune suppression in syngeneic mice). Integrated RNA-sequencing and antibody array profiling identified C-X-C chemokines, in particular CXCL1/3, were depleted by SLC25A22 knockout. SLC25A22 loss reduced CXCL1/3 mRNA as well as secretion in CRC cells (IDDF2021-ABS-0183 Figure 4. SLC25A22 regulate the expression and secretion of chemokines CXCL1 and CXCL3). CXCL1/3 functions as chemoattractants for MDSC via its receptor CXCR2. Indeed, the conditioned medium from SLC25A22 knockout CRC cell showed impaired ability to promote MDSC migration compared to the control medium. CXCL1-siRNA, anti-Cxcl1 neutralizing antibody or CXCR2 inhibitor impaired SLC25A22-induced MDSC migration, inferring an underlying role of CXCL1-CXCR2 interaction and in attracting MDSC infiltration. (IDDF2021-ABS-0183 Figure 5. SLC25A22 recruits MDSC migration via CXCL1/CXCR2 axis, IDDF2021-ABS-0183 Figure 6. SLC25A22 recruits MDSC migration via CXCL1/CXCR2 axis) Conclusions Our work suggests a SLC25A22-chemokine axis that promotes an immune suppressive microenvironment in KRAS-mutant CRC and implies that SLC25A22 constitutes a novel target for immunotherapies.

Up-regulated SLC25A39 promotes cell growth and metastasis via regulating ROS production in colorectal cancer

25-hydroxycholesterol Regulates Migration, Invasion and EMT of Colorectal Cancer through miR-92a-3p/ACAA1/NF-κB Pathway

SLC12A8 upregulation promotes colorectal cancer progression and chemoresistance

SLC25A19 drives colorectal cancer progression by regulating p53

SLC25A1 promotes tumor growth and survival by reprogramming energy metabolism in colorectal cancer

SLC25A18 has prognostic value in colorectal cancer and represses Warburg effect and cell proliferation via Wnt signaling.

SLC38A1 Promotes Proliferation and Migration of Human Colorectal Cancer Cells

Comprehensive Analyses of Solute Carrier Family Members Identify SLC12A2 As a Novel Therapy Target for Colorectal Cancer

Long non-coding RNA CCAT1 promotes colorectal cancer progression by regulating miR-181a-5p expression

Abstract A001: Colorectal Cancer Cell-Derived Exosomes Containing Mir-183-5p Regulate Angiogenesis Via FOXO1

A Prognosis Marker SLC2A3 Correlates with EMT and Immune Signature in Colorectal Cancer

Blockade of the Amino Acid Transporter SLC6A14 Suppresses Tumor Growth in Colorectal Cancer.

IDDF2021-ABS-0183 SLC25A22 Drives Immune Suppression in Kras-Mutant Colorectal Cancer

SLC14A1 and TGF-β signaling: a feedback loop driving EMT and colorectal cancer metachronous liver metastasis

Aberrant SLC6A14 Expression Promotes Proliferation and Metastasis of Colorectal Cancer via Enhancing the JAK2/STAT3 Pathway

SLC11A1 associated with tumor microenvironment is a potential biomarker of prognosis and immunotherapy efficacy for colorectal cancer

S100P Contributes to Promoter Demethylation and Transcriptional Activation of SLC2A5 to Promote Metastasis in Colorectal Cancer

Colorectal cancer with low SLC35A3 is associated with immune infiltrates and poor prognosis

SLCO1B3 promotes colorectal cancer tumorigenesis and metastasis through STAT3

Integrated analysis of transcriptomics, proteomics and metabolomics data reveals the role of SLC39A1 in renal cell carcinoma

Increased expression of Solute carrier family 12 member 5 via gene amplification contributes to tumour progression and metastasis and associates with poor survival in colorectal cancer.